medigraphic.com
Colegio de Medicina Interna de México.

2018, Número 3

<< Anterior Siguiente >>

Med Int Mex 2018; 34 (3)


Reunión multidisciplinaria de expertos para el diagnóstico y tratamiento de la osteoartritis. Actualización basada en evidencias

Espinosa-Morales R, Alcántar-Ramírez J, Arce-Salinas CA, Chávez-Espina LM, Esquivel-Valerio JA, Gutiérrez-Gómez JJ, De la Lanza L, Martínez-Hernández JL, Méndez-Medina C, Robles-San Román M, Santillán-Barrera E, Torres-Roldán F, Sosa-García JO, Aldrete-Velasco J, Romero-González A

Idioma: Español
Referencias bibliográficas: 101
Paginas: 443-476
Archivo PDF: 1060.21 Kb.


RESUMEN

La osteoartritis es una enfermedad articular crónica degenerativa, es la afección articular observada con más frecuencia en la población adulta y una de las principales causas de discapacidad en todo el mundo, por lo que es de importancia el diagnóstico y tratamiento en las fases tempranas de la enfermedad. En la actualidad los nuevos tratamientos, además de aliviar el dolor, pueden disminuir la limitación funcional y modificar el curso de la enfermedad. El objetivo de este artículo es actualizar la evidencia acerca del diagnóstico y de las nuevas formas de tratamiento de la osteoartritis, así como evaluar los cambios en la evidencia que ha habido en relación con la guía anterior. Para la elaboración de la guía motivo de esta reunión, se contó con la participación de especialistas en Medicina Interna, Reumatología, Ortopedia y Rehabilitación física, un bibliotecario y un experto en metodología; se realizó una búsqueda extensa en PubMed y en otros sitios web especializados. Se estableció una serie de recomendaciones y niveles de evidencia basados en la bibliografía consultada. Se concluye que la osteoartritis es una enfermead compleja que implica múltiples factores de riesgo, por lo que es importante tomar en cuenta que el tratamiento es multidisciplinario y consta de un enfoque no farmacológico y uno farmacológico; sin embargo, es necesario crear una cultura preventiva de la osteoartritis en los médicos tratantes, en la que se eduque y se dé información al paciente para evitar que la enfermedad progrese.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Programa Nacional de Salud 2007-2012. Por un México sano: construyendo alianzas para una mejor salud. Secretaría de Salud, México 2007.

  2. Cajigas JC, Ariza R, Espinosa R y col. Guía de práctica clínica basada en la evidencia para el diagnóstico y tratamiento de la osteoartritis. Med Int Mex 2011;27(6):552-572.

  3. Espinosa MR, Arce SC, Cajigas MJ y col. Reunión multidisciplinaria de expertos para el diagnóstico y tratamiento de la osteoartritis. Actualización basada en la evidencia. Med Int Mex 2013;29(1):67-92.

  4. Carlos Manterola D, Daniela Zavando M. Cómo interpretar los “Niveles de evidencia” en los diferentes escenarios clínicos. Rev Chilena de Cirugía 2009;16:582-595

  5. Solís CU, de Armas HA, Bacallao CA. Osteoartritis. Características sociodemográficas. Rev Cub Reum 2014. Volumen XVI, Número 2; 97-103.

  6. Nicola Veronese, Emanuele Cereda, Stefania Maggi, et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Sem Arth Rheum. Elsevier Inc. 2016. 0049-0172

  7. Peláez-Ballestas I, Sanin LE, Moreno-Montoya J, et al. Epidemiology of the Rheumatic Disease in Mexico. A Study of 5 Regions Based on the COPCORD Methodology. J Rheum 2011;38(Suppl 86):3-8.

  8. Pereira D, Peleteiro B, Araujo J, et al. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthritis Cartilage 2011;19:1270-1285.

  9. Loeser RF, Hunter D, Ramirez C, et al. Pathogenesis of osteoarthritis. In: UpToDate (último acceso el 19 de enero de 2016).

  10. Altman R, Asch R, Bloch D. Development of criteria for the classification and reporting of OA. Classification of OA of the knee. Arthr Rheum 1986;29:1039-1049.

  11. Altman R. Criteria for classification of clinical osteoarthrosis. J Rheumatol 1991;18(27):10-12.

  12. Chapple C, Nicholson H, Baxter D, et al. Patient Characteristics That Predict Progression of Knee Osteoarthritis: A Systematic Review of Prognostic Studies. Arthritis Care Res 2011;63(8):1115-1125.

  13. Bijlsma WJ, Berenbaum F, Lafeber F. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377:2115-26.

  14. Nevitt MC, Felson DT. Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. Ann Rheum Dis 1996;55:673-676.

  15. Hunter DJ, Zhang W, Conoghan P, et al. Systematic review of the concurrent and predictive validity of MRI biomarkersin OA. Osteoarthritis Cartilage 2011;557-588.

  16. Yoshimura N, Muraki S, Oka H, et al. Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD study. Osteoarthritis Cartilage 2012;1-10.

  17. Farshid Guilak. Biomechanical factors in osteoarthritis. Best Pract Res Clin Rheum 2011;815-823.

  18. Hoch JM, Mattacola CG, Medina McKeon JM, et al. Serum cartilage oligomeric matrix protein (sCOMP) is elevated in patients with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage 2011;19(11):1396- 1404.

  19. Doherty M, Abhishek A, Hunter D, et al. Clinical manifestations and diagnosis of osteoarthritis. In: UpToDate (último acceso el 19 de enero de 2016).

  20. Taylor C, Carballido-Gamio J, Majumdar S, et al. Comparison of quantitative imaging of cartilage for osteoarthritis: T2, T1ρ, dGEMRIC and contrast-enhanced computed tomography. Magn Reson Imaging 2009;27:779-784.

  21. Jobke B, Bolbos R, Saadat E, et al. Mechanism of disease in early osteoarthritis: application of modern MR imaging techniques-a technical report. Magn Reson Imaging 2013;31:156-161.

  22. Roemer FW, Kwoh CK, Hannon MJ, et al. Risk factors for magnetic resonance imaging-detected patellofemoral and tibiofemoral cartilage loss during a six-month period. Arthritis Rheum 2012;64(6):1888-1898.

  23. Felson DT, Chaisson CE, Hill CL, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Int Med 2001;134:541-549.

  24. Roemer FW, Neogi T, Nevitt MC, et al. Subchondral bone marrow lesions are highly associated with, and predict subcondral bone attrition longitudinally: the MOST study. Osteoarthritis Cartilage 2010;18:47-53.

  25. Kalunian KC, Tugwell P, Ramirez C Murtis. Nonpharmacologic therapy of osteoarthritis. In: UpToDate (último acceso el 19 de enero de 2016).

  26. American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the Treatment of Osteoarthritis of the Knee (Non-Arthroplasty). Rosemont (IL). American Academy of Orthopaedic Surgeons (AAOS); 2008.

  27. Hochberg M, Altman R, Toupin K, et al. American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res 2012;64(4):465-474.

  28. Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebocontrolled trials. Eur J Pain 2007 Feb;11(2):125-38.

  29. Roberts E, Delgado NV, Buckner S, et al.. Paracetamol: Not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016;75:552-559. http://dx.doi.org/10.1136/annrheumdis-2014-206914)

  30. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 2008;16:137-1362.

  31. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64(5):669-681.

  32. Kon E, Filardo G, Drobnic M. Non-surg cal management of early knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2012;20:436-449.

  33. Derry S, Conaghan P, Da Silva JAP, et al. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD007400. DOI: 10.1002/14651858.CD007400.pub3.)

  34. García SR, Calcerrada N. Grupo de trabajo de la guía de práctica clínica del manejo del paciente con artrosis de rodilla en atención primaria. Madrid: Unidad de Evaluación de Tecnologías Sanitarias (UETS), Áreas de Investigación y Estudios Sanitarios. Agencia Laín Entralgo; 2006.

  35. Altman R. Brief review new guidelines for topical NSAIDs in the osteoarthritis treatment paradigm. Curr Med Res Opin 2010;26(12):2871-2876.

  36. National Institute Clinical Excellence (NICE) Osteoarthritis National Clinical Guideline for Care and Management in adults, 2008.

  37. Klippel J, Stone J, et al. Primer on the Rheumatic Diseases. 13a ed. Atlanta: Arthritis Foundation, 2008;634-642.

  38. Flood J. The role of acetaminophen in the treatment of osteoarthritis. Am J Man Care 2010;16(Suppl2):S48-S54.

  39. Verkleij SPJ, Luijsterburg PAJ, Bohnen AM, et al. NSAIDs vs acetaminophen in knee and hip osteoarthritis: a systematic review regarding heterogeneity influencing the outcomes. Osteoarthritis Cartilage 2011;19:921-929.

  40. Ministry of Health Singapore (MOH). Clinical Practice Guideline Osteoarthritis of the Knee, 2007.

  41. Espinosa R, Peña A. Osteoartritis. En Robles M, Cajigas JC, Ventura L. Reumatología para el clínico. México: Editorial Alfil, 2011;305-315.

  42. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Riesgo cardiovascular de dosis altas de ibuprofeno o dexibuprofeno: recomendaciones de uso. 13 de abril de 2015 (consultado 23 enero 2017).

  43. Food and Drug Administration [Internet]. FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Drug Safety Communications [9 Jul 2015]. [consultado 23 enero 2017]. Disponible en: http://www.fda.gov/Drugs/DrugSafety/ ucm451800.htm

  44. Flouvat B, Stheneur A, Massias P. Profil pharmacocinetique d’une formulation a Liberation prolongee de ketoprofene. Sem Hop Paris 1983;59(46):3187-3190.

  45. Strand V. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol 2011;38;2625- 2634.

  46. de Abajo FJ, Gil MJ, García Poza P, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf 2014 Nov;23(11):1128-38. doi: 10.1002/pds.3617

  47. MacDonald TM, Hawkey CJ, Ford I, et al. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs Celecoxib Outcome Trial (SCOT). Eur Heart J 2016. pii: ehw387.

  48. Nissen SE, Yeomans ND, Solomon DH, et al. PRECISION Trial Investigators Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med 2016;375(26):2519-29.

  49. De Lemos BP, Xiang J, Benson C, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: A double-blind, randomized, dose-ranging trial. Am J Ther 2011;18(39):216-226.

  50. Boyer KA, Angst MS, Asay J, et al. Sensitivity of gait parameters to the effects of anti-inflammatory and opioid treatments in knee osteoarthritis patients. J Orthop Res 2012;30/7:1118-1124.

  51. Zhang W, Nuki G, Moskowitz R, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-499.

  52. Marks JL, van der Heijde DM, Colebatch AN, et al. Pain pharmacotherapy in patients with inflammatory arthritis and current cardiovascular or renal disease: a Cochrane systematic review. J Rheumatol Supl 2012;90:81-84.

  53. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11(1):33-41.

  54. Lyttle JR, Urquhart DM, Cicuttini FM, et al. Antidepressants for osteoarthritis. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD012157.

  55. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebocontrolled trial. Pain 2009;146(3):253-260.

  56. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-1522.

  57. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis sympotms: a randomized, double-blind, placebo-controlled study using acetoaminophen as a side comparator. Arthritis Rheum 2007;56(2):555-567.

  58. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354(8):795-808.

  59. Singh JA, Noorbaloochi S, MacDonald R, et al. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015.

  60. Hochberg MC, Martel-Pelletier J, Monfort J, et al. MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016;75(1):37-44

  61. Fransen M, Agaliotis M, Nairn L, et al. LEGS study collaborative group. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomized placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2015;74(5):851-8.

  62. Young Ho Lee, Jin-Hyun Woo, Seong Jae Choi, et al. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010;30(3):357-363.

  63. Pvelká K, Gatterová J, Olejarová M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis. Arch Int Med 2002;162(18):2113-2123.

  64. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a twoyear, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60(2):524-533.

  65. Du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther 2014;142(3):362-74.

  66. Gabay C, Medinger-Sadowski C, Gascon D, Kolo F, Finckh A. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum 2011 Nov;63(11):3383-91. doi: 10.1002/art.30574.

  67. Zeng C, Wei J, Li H, et al. Effectiveness and safety of glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep 2015 Nov 18;5:16827. doi: 10.1038/srep16827

  68. Gilbert AM, Bikker JA, O’Neil SV. Advances in the development of novel aggrecanase inhibitors. Expert Opin Ther Pat 211;21(1):1-12.

  69. Vijaykumar M. Baragi, Gabriel Becher, Alison M. Bendele, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009;60(7):2008-2018.

  70. Strand V, McIntyre LF, Beach WR, et al. Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. J Pain Res 2015;8:217-28.

  71. Cardona-Muñoz JI. La viscosuplementación como tratamiento alternativo en la osteoartritis. Ortho-Tips 2012;8(2):87-92.

  72. Legré-Boyer V. Viscosupplementation: techniques, indications, results. Orthopaed Traumatol Surg Res 2015;101:S101-8.

  73. Iannitti T, Lodi D, Palmieri B. Intra-articular injections for the treatment of osteoarthritis: focus on the clinical use of hyaluronic acid. Drugs RD 2011;11(1):13-27.

  74. Rivera F. Single intra-articular injection of high molecular weight hyaluronic acid for hip osteoarthritis. J Orthopaed Traumatol 2016;17:21-6.

  75. Henrotin Y, Raman R, Richette P, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthr Rheum 2015; doi: http://dx.doi.org/10.1016/j.

  76. Navarro-Sarabia F, Coronel P, Collantes E, et al. AMELIA study group. A 40-month multicentre, randomised placebocontrolled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoartritis: the AMELIA Project. Ann Rheum Dis 2011;70(11):1957-1962.

  77. Bannuru RR, Natov NS, Dasi US, et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis–meta-analysis. Osteoarthritis Cartilage 2011;19(6):611-619.

  78. Du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther 2014;142(3):362-74.

  79. Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee a randomized, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis 2010;69:113-119.

  80. Migliore A, Bizzi E, Massafra U, et al. The impact of treatment with hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr Med Res Opin 2012;28(5):755-760.

  81. Yuanyuan W, Stephen H, Fahad H, et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculosk Dis 2011;12:1-9.

  82. Migliore A, Giovannangeli F, Bizzi E, et al. Treatment of osteoarthritis knee pain: update on use of intra-articular hylan G-F 20. Orthop Res Rev 2010;2:107-118.

  83. Wang Y, Hall S, Hanna F, et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculosk Dis 2011;12:195 (1-9); http://www.biomedcentral.com/1471-2474/12/195.

  84. Wobig M, Bach G, Beks P, et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular- weight hyaluronan. Clin Ther 1999;21(9):1549-62.

  85. Bellamy N, Campbell J, Robinson V, et al; Revisión Cochrane. Tratamiento con corticosteroide intraarticular para la osteoartritis de rodilla. John Wiley & Sons, Oxford (UK), 2006.

  86. Jüni P, Hari R, Rutjes AWS, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD005328. DOI: 10.1002/14651858.CD005328.pub3

  87. Jordan KM, Arden NK, Doherty M, et al. European League Against Rheumatism (EULAR) Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145-55.

  88. Maheu E, Cadet C, Marty M, et al. Evaluation of the structure- modifying effect of avocado-soybean unsaponifiables (ASU) in hip osteoarthritis (OA): results of the ERADIAS study, a 3-year, prospective, randomized, double-blind, placebo controlled trial. Program and abstracts of the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting; 2009:17-21.

  89. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD002947. DOI:10.1002/14651858. CD002947.pub2.

  90. Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD005117. DOI: 10.1002/14651858. CD005117.pub3

  91. Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res 2003;311:393-399.

  92. Schunck M, Schulze CH, Oesser S. Collagen peptide supplementation stimulates proteoglycan biosynthesis and aggrecan expression of articular chondrocytes. Osteoarthritis Cartilage 2009;S143.

  93. Bello AE, Oesser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. Curr Med Res Op 2006;22:1-12.

  94. Wang-Saegusa A, Cugat R, Ares O, et al. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Arch Orthop Traum Surg 2011;131(3):311-317.

  95. McNickle AG, L’Heureux DR, Yanke AB, et al. Outcomes of autologous chondrocyte implantation in a diverse patient population. Am J Sports Med 2009;37:7:1344-1350.

  96. Richmond J, Hunter D, Irrgang J, et al. American Academy of Orthopaedic Surgeons Clinical Practice Guideline on the Treatment of Osteoarthritis of the Knee. (Non-Arthroplasty). Rosemont (IL): American Academy of Orthopaedic Surgeons (AAOS); 2010. J Bone Joint Surg Am 2010;92:990-3.

  97. Peter WF, Jansen EJ, Hurkmans H, et al. Physiotherapy in hip and knee osteoarthritis. Development of a practice guideline concerning initial assessment, treatment and evaluation. Acta Reuma 2011;36:268-281.

  98. Osteoarthritis: National Clinical Guideline for care and management in adults. National Collaborating Centre for Chronic Conditions (UK) London: Royal College of Physicians (UK);2008.

  99. Hawker GA, Mian S, Bednis K, et al. Osteoarthritis year 2010 in review: non-pharmacologic therapy. Osteoarthritis Cartilage 2011;19(4):366-74.

  100. Rosa UH, Velázquez J, Lara C. Comparison of the effectiveness of isokinetic vs isometric therapeutic exercise in patients with osteoarthritis of knee. Reumathol Clin 2012;8(1):10-14.

  101. Lequesne MG, Merfor. Osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol 1987;(Suppl 65):85-89.




2020     |     www.medigraphic.com